These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 26295044)

  • 1. Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies.
    Rocha NP; de Miranda AS; Teixeira AL
    Biomed Res Int; 2015; 2015():628192. PubMed ID: 26295044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson's disease.
    Whitton PS
    Curr Opin Investig Drugs; 2010 Jul; 11(7):788-94. PubMed ID: 20571974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An inflammatory pathomechanism for Parkinson's disease?
    Wersinger C; Sidhu A
    Curr Med Chem; 2006; 13(5):591-602. PubMed ID: 16515523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair.
    Vivekanantham S; Shah S; Dewji R; Dewji A; Khatri C; Ologunde R
    Int J Neurosci; 2015; 125(10):717-25. PubMed ID: 25364880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective potential of ferulic acid in the rotenone model of Parkinson's disease.
    Ojha S; Javed H; Azimullah S; Abul Khair SB; Haque ME
    Drug Des Devel Ther; 2015; 9():5499-510. PubMed ID: 26504373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation in Parkinson's disease.
    Tufekci KU; Meuwissen R; Genc S; Genc K
    Adv Protein Chem Struct Biol; 2012; 88():69-132. PubMed ID: 22814707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson's disease.
    Kaur K; Gill JS; Bansal PK; Deshmukh R
    J Neurol Sci; 2017 Oct; 381():308-314. PubMed ID: 28991704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugs.
    Bassani TB; Vital MA; Rauh LK
    Arq Neuropsiquiatr; 2015 Jul; 73(7):616-23. PubMed ID: 26200058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation in Parkinson's Disease: Mechanisms and Therapeutic Implications.
    Pajares M; I Rojo A; Manda G; Boscá L; Cuadrado A
    Cells; 2020 Jul; 9(7):. PubMed ID: 32674367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel anti-inflammatory therapy for Parkinson's disease.
    Gao HM; Liu B; Zhang W; Hong JS
    Trends Pharmacol Sci; 2003 Aug; 24(8):395-401. PubMed ID: 12915048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.
    Tansey MG; McCoy MK; Frank-Cannon TC
    Exp Neurol; 2007 Nov; 208(1):1-25. PubMed ID: 17720159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation in Parkinson's disease: an update.
    Smith PF
    Curr Opin Investig Drugs; 2008 May; 9(5):478-84. PubMed ID: 18465657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular phenotypes as inflammatory mediators in Parkinson's disease: Interventional targets and role of natural products.
    Jiang X; Ganesan P; Rengarajan T; Choi DK; Arulselvan P
    Biomed Pharmacother; 2018 Oct; 106():1052-1062. PubMed ID: 30119171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory response in Parkinson's disease (Review).
    Yan J; Fu Q; Cheng L; Zhai M; Wu W; Huang L; Du G
    Mol Med Rep; 2014 Nov; 10(5):2223-33. PubMed ID: 25215472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson's disease models are mediated by GPR109A-dependent mechanisms.
    Fu SP; Wang JF; Xue WJ; Liu HM; Liu BR; Zeng YL; Li SN; Huang BX; Lv QK; Wang W; Liu JX
    J Neuroinflammation; 2015 Jan; 12():9. PubMed ID: 25595674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation and Parkinson's disease.
    Wersinger C; Sidhu A
    Curr Drug Targets Inflamm Allergy; 2002 Sep; 1(3):221-42. PubMed ID: 14561187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phytic acid attenuates inflammatory responses and the levels of NF-κB and p-ERK in MPTP-induced Parkinson's disease model of mice.
    Lv Y; Zhang Z; Hou L; Zhang L; Zhang J; Wang Y; Liu C; Xu P; Liu L; Gai X; Lu T
    Neurosci Lett; 2015 Jun; 597():132-6. PubMed ID: 25929185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
    Heng Y; Zhang QS; Mu Z; Hu JF; Yuan YH; Chen NH
    Toxicol Lett; 2016 Jan; 243():7-21. PubMed ID: 26723869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory Mechanisms in Parkinson's Disease: From Pathogenesis to Targeted Therapies.
    Lee SYH; Yates NJ; Tye SJ
    Neuroscientist; 2022 Oct; 28(5):485-506. PubMed ID: 33586516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.
    Tsai SJ
    Med Hypotheses; 2007; 69(6):1219-21. PubMed ID: 17548170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.